The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy.

Elizabeth L CarpenterSpencer G Van DecarPatrick M McCarthyFranklin A ValderaAlexandra M AdamsAnne E O'SheaTodd R SmolinskyKatryna ThomasGuy T CliftonTimothy E NewhookGeorge E PeoplesDaniel W NelsonTimothy J Vreeland

Published in: Journal of surgical oncology (2024)

Response to NAT appears to correlate with the benefit of AT following pancreaticoduodenectomy; patients who have a favorable response to NAT may not benefit from AT.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
lymph node
rectal cancer
prognostic factors
peritoneal dialysis
stem cells
locally advanced
mesenchymal stem cells
radiation therapy
patient reported outcomes
bone marrow
replacement therapy